Stockscreener 앱 받기
25.99
2.04%
-0.54
전일 마감가:
$26.53
열려 있는:
$26.7
하루 거래량:
1.34M
Relative Volume:
0.89
시가총액:
$4.40B
수익:
$890.53M
순이익/손실:
$30.57M
주가수익비율:
144.39
EPS:
0.18
순현금흐름:
$80.53M
1주 성능:
-2.95%
1개월 성능:
-3.02%
6개월 성능:
+15.25%
1년 성능:
+48.34%
1일 변동 폭
$25.81
$26.70
1주일 범위
$25.81
$27.06
52주 변동 폭
$13.40
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
명칭
Acadia Pharmaceuticals Inc
전화
858-558-2871
주소
12830 EL CAMINO REAL, SAN DIEGO
ACAD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
25.99 | 4.49B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-05-21 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2025-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-03-12 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-12 | 재확인 | Needham | Buy |
| 2024-01-30 | 개시 | Robert W. Baird | Outperform |
| 2024-01-24 | 업그레이드 | Needham | Hold → Buy |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-10-10 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-11-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-11-01 | 개시 | Loop Capital | Hold |
| 2022-08-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-08-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-21 | 다운그레이드 | Jefferies | Buy → Underperform |
| 2022-06-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-03-16 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-21 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-06-10 | 개시 | Berenberg | Hold |
| 2021-04-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-05 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2021-03-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-11-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 개시 | Morgan Stanley | Overweight |
| 2020-07-07 | 업그레이드 | Stifel | Hold → Buy |
| 2020-04-16 | 개시 | Jefferies | Buy |
| 2020-03-31 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2019-12-16 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-01 | 개시 | RBC Capital Mkts | Outperform |
| 2019-09-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | 재확인 | Needham | Buy |
| 2018-12-10 | 개시 | Canaccord Genuity | Hold |
| 2018-09-21 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | 재확인 | Stifel | Hold |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-08-06 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
Investing in ACADIA Pharmaceuticals (NASDAQ:ACAD) a Year Ago Would Have Delivered You a 51% Gain - 富途牛牛
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup - Chartmill
Is It Time To Reconsider ACADIA Pharmaceuticals (ACAD) After Recent Share Price Weakness - Sahm
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Swings - Yahoo Finance
Is It Time To Reassess ACADIA Pharmaceuticals (ACAD) After Its Recent Share Price Surge - Yahoo Finance
Acadia projects $1.7 billion in 2028 sales for NUPLAZID and DAYBUE - Investing.com Nigeria
Neuren Pharmaceuticals flags DAYBUE global sales potential of US$700m by 2028 - Proactive financial news
Acadia Pharmaceuticals (ACAD) Projects Over $1B in 2025 Sales - GuruFocus
ACADIA Pharmaceuticals Clarifies Form 8-K Disclosure Treatment - TipRanks
Acadia Pharma anticipates 2025 net sales to exceed $1 billion - StreetInsider
ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Maps Key Remlifansirin Readouts at JPM Conf - MarketBeat
Acadia CEO Bands With Peers To Lobby Against MFN Drug Pricing for Small Biotech - BioSpace
ACADIA projects $1.7 billion in 2028 sales, launches new DAYBUE formulation - StreetInsider
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Lobbying Update: $30,000 of ACADIA PHARMACEUTICALS lobbying was just disclosed - Quiver Quantitative
Published on: 2026-01-13 01:54:16 - Улправда
Acadia Pharmaceuticals Focuses on Next-Gen Neuroscience - marketscreener.com
Watch Acadia Pharmaceuticals Focuses on Next-Gen Neuroscience - Bloomberg.com
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Wall Street Zen Upgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) to "Buy" - MarketBeat
Behavioral Patterns of ACAD and Institutional Flows - Stock Traders Daily
Can ACADIA Pharmaceuticals Inc. stock attract ESG capital inflows2025 Analyst Calls & Growth Focused Stock Pick Reports - ulpravda.ru
How ACADIA Pharmaceuticals Inc. stock compares to industry benchmarks2025 Market Outlook & AI Driven Stock Reports - Улправда
Acadia drops development of carbetocin in PWS - The Pharma Letter
Pullback Watch: Will ACADIA Pharmaceuticals Inc. stock outperform international peersJuly 2025 Review & Fast Gain Stock Trading Tips - ulpravda.ru
Will ACADIA Pharmaceuticals Inc. stock beat EPS estimatesProduct Launch & Risk Adjusted Swing Trade Ideas - ulpravda.ru
Will ACADIA Pharmaceuticals Inc. stock see PE expansionTrade Performance Summary & Reliable Price Breakout Signals - Улправда
Is ACADIA Pharmaceuticals Inc. stock a defensive play in 2025Forecast Cut & Free Reliable Trade Execution Plans - Улправда
Stock Market Recap: Will ACADIA Pharmaceuticals Inc. stock outperform international peersJuly 2025 Drop Watch & AI Powered Buy and Sell Recommendations - ulpravda.ru
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Momentum - Sahm
ACADIA Pharmaceuticals (ACAD) Sees Target Price Raised by Citigr - GuruFocus
UBS Raises Price Target to $40 for ACADIA Pharmaceuticals (ACAD) - GuruFocus
ACADIA Pharmaceuticals Inc. $ACAD Shares Purchased by Allspring Global Investments Holdings LLC - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Cut to "Hold" at Wall Street Zen - MarketBeat
What drives ACADIA Pharmaceuticals Inc stock priceMean Reversion Trades & Outstanding Wealth Building - earlytimes.in
ACADIA Pharmaceuticals Earnings Notes - Trefis
Insider Sell: Is ACADIA Pharmaceuticals Inc stock in correction or buying zoneIndex Update & Risk Controlled Swing Alerts - moha.gov.vn
(ACAD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Deutsche Bank Upgrades ACADIA Pharmaceuticals (ACAD) - MSN
Performance Recap: Can ACADIA Pharmaceuticals Inc stock hit analyst price targetsWeekly Earnings Recap & Verified Swing Trading Watchlists - moha.gov.vn
Rice Hall James & Associates LLC Sells 54,869 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals Inc. $ACAD Holdings Decreased by Assenagon Asset Management S.A. - MarketBeat
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? - AOL.com
Here's why Acadia Pharmaceuticals (ACAD) is a strong momentum stock - MSN
ACADIA Pharmaceuticals Advances Alzheimer’s Disease Psychosis Study with ACP-204 - MSN
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock - sharewise.com
Acadia Pharmaceuticals stock reaches 52-week high at $27.73 By Investing.com - Investing.com Nigeria
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year HighHere's Why - MarketBeat
Acadia Pharmaceuticals stock reaches 52-week high at $27.73 - Investing.com
Acadia Pharmaceuticals price target raised to $29 from $24 at Mizuho - MSN
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Its Strong 1-Year Share Price Rally - Yahoo Finance
Acadia Pharmaceuticals Inc (ACAD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):